| abstract |
(57) [Summary] [Objective] To provide a plasmin inhibitor which has high specificity for plasmin, is more effective, and has fewer side effects. [Structure] A sulfated compound selected from the group consisting of β (1 → 3) glucan in which glucose residue is bound by β (1 → 6) glycoside bond and sulfated product of oligosaccharide derived from the glucan is used as an active ingredient. A plasmin inhibitor characterized in that |